CA15-3 is a heterogeneous, 300 kDa glycoprotein. It was initially defined by using two monoclonal antibodies 115D8 and DF3, raised against breast carcinoma cells, and since then has been studied as a potential marker for metastatic breast cancer. CA15-3 is a normal product of breast cells, but in cancer it is frequently over-expressed. CA15-3 is used for the monitoring of the course and response to therapy of breast cancer. It is elevated in up to 70% of patients with metastatic disease, however, is only elevated in 3% of those with localized cancer. SCIPAC CA15-3 antibody pairs have been tested on real patient samples across a dynamic range, and show excellent performance compared with antibodies available in commercial immunoassays currently on the market.
| Abbreviation | CA15-3 mAb |
| Synonyms | Cancer Antigen 15-3 mAb |
| Molecular Weight | 300 kDa (CA15-3 Antigen) |
| Variant Name | Product Code | Purity | |
|---|---|---|---|
+ |
CA15-3 mAb clone K6A5 | BM236-K6A5 | > 95% pure |
+ |
CA15-3 mAb clone U9H3 | BM236-U9H3 | >95% pure |
+ |
CA15-3 mAb clone V2G9 | BM236-V2G9 | > 95% pure |
+ |
CA15-3 mAb clone K2F4 | BM236-K2F4 | > 95% pure |
